Effect of low caloric diet in fatty liver

Effects of the hypocaloric DASH diet (Dietary Approaches to Stop Hypertension) on liver enzymes, lipid profiles and insulin resistance in patients with fatty liver

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201311215623N14

Enrollment

Registered

2013-12-11

Start date

2014-11-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: DASH diet, 6 serving vegetables, 6 serving fruits, rich in fiber and whole grains, daily for 8 weeks. Intervention 2: Control group: Standard diet, 4 serving vegeta

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects aged 25-75 years All patients with laboratorial and sonographical criteria of fatty liver.

Exclusion criteria

Exclusion criteria: Consumption of alcohol Pregnancy and lactation Hereditary hemochromatosis History of jejunoileal bypass surgery or gastroplasty Taking hepatotoxic drugs such as calcium channel blocker and high doses of synthetic estrogens History of hypothyroidism Cushing’s syndrome Renal failure and kidney stones

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.	—

Secondary

Measure	Time frame
AST. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Grade of fatty liver. Timepoint: Baseline and End-of-trial. Method of measurement: Sonography.	—

Measure

Time frame

AST. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Grade of fatty liver. Timepoint: Baseline and End-of-trial. Method of measurement: Sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026